

News Release

May 15, 2024
Carna Biosciences, Inc.

Carna announces acceptance of a poster on AS-1763 for presentation at European Hematology Association (EHA) 2024

Carna Biosciences, a clinical-stage biopharmaceutical company focusing on the discovery and development of innovative therapies to treat serious unmet medical needs, announces that preliminary safety and efficacy results from an ongoing Phase 1b study of AS-1763 will be presented at the European Hematology Association (EHA) 2024 Hybrid Congress, taking place June 13-16 in Madrid, Spain.

AS-1763, an investigational small molecule drug designed to non-covalently inhibit Bruton's tyrosine kinase (BTK) in a highly selective manner, is currently under development for the treatment of patients with chronic lymphocytic leukemia (CLL) and other B-cell malignancies who have developed resistance or are intolerant to at least two prior lines of systemic therapy including a covalent BTK inhibitor.

The poster will be presented by Nitin Jain, MD, Department of Leukemia, The University of Texas MD Anderson Cancer Center and all the other principal investigators at the participating clinical sites.

Presentation Details

Abstract Code: P653

Poster title:	Preliminary safety and efficacy results from a Phase 1b study of oral non-covalent BTK inhibitor AS-1763 in patients with previously treated B-cell malignancies
Session:	Poster session
Presenter:	Nitin Jain ¹ , Catherine C. Coombs ² , James D'Olimpio ³ , Nirav N Shah ⁴ , Jacqueline Barrientos ⁵ , Seung Tae Lee ⁶ , Andrew Gillis-Smith ⁷ , Shuo Ma ⁸ , Shirou Kirita ⁹ , Masaaki Sawa ⁹ , Kyoko Miyamoto ¹⁰ , Akinori Arimura ^{9,10} , William Wierda ¹ , Varsha Gandhi ¹¹ , Javier Pinilla-Ibarz ¹²

1. The University of Texas MD Anderson Cancer Center, 2. University of California Irvine Health, 3. Clinical Research Alliance, 4. Medical College of Wisconsin, 5. Mount Sinai Medical Center, 6. Greenebaum Comprehensive Cancer, University of Maryland, 7. University of Massachusetts, 8. Robert H. Lurie Comprehensive Cancer Center, Northwestern University, 9. Carna Biosciences, Inc., 10. CarnaBio USA, Inc., 11. The University of Texas MD Anderson Cancer Center, Department of Experimental Therapeutics, 12. H Lee Moffitt Cancer Center and Research Institute

The abstract is now available at:

[EHA Library - The official digital education library of European Hematology Association \(EHA\) \(ehaweb.org\)](https://ehaeb.org)

About AS-1763

AS-1763 is a highly selective, orally bioavailable, non-covalent inhibitor of both the wild type and mutant BTKs for the treatment of CLL and other B cell malignancies. Covalent BTK inhibitors including ibrutinib are key therapeutic options for patients with B cell malignancies. However, patients are reported to develop resistance during the treatment due to substitution of cysteine residue at 481 position with serine (C481S mutation) in BTK, which reduces the efficacy of the covalent BTK inhibitors. In addition, the emergence of other types of resistance mutations to non-covalent BTK inhibitor, recently approved pirtobrutinib, has been reported. AS-1763 potently inhibited both wild type and those mutant BTKs, strongly suggesting that AS-1763 will be a new therapeutic option for treating patients with B cell malignancies both having wild type and resistance mutations in BTK. Carna is advancing development of AS-1763 as a next-generation BTK inhibitor.

Contact:

Corporate Planning

Carna Biosciences, Inc.

TEL: +81-78-302-7075

<https://www.carnabio.com/english/>